At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Pre-Mkt 09-23 09:15:47 EDT
29.40
+1.09
+3.85%
盘前29.40
+0.000.00%
08:59 EDT
High29.55Low28.37Vol849.46K
Open28.63D1 Closing28.31Amplitude4.17%
Mkt Cap2.59BTradable Cap1.94BTotal Shares88.16M
T/O24.81MT/O Rate1.29%Tradable Shares66.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys Therapeutics Chief Commercial Officer Eric Warren Disposes of Common Shares Worth USD 209,111.85
Reuters  ·  06:49
Mineralys Therapeutics Chief Commercial Officer Eric Warren Disposes of Common Shares Worth USD 209,111.85
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-22 04:05
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Mineralys Therapeutics Director Daphne Karydas Sells 3,000 Shares for $85,740
Reuters  ·  09-18
Mineralys Therapeutics Director Daphne Karydas Sells 3,000 Shares for $85,740
Mineralys Therapeutics Grants Inducement Equity Awards Covering 52,080 Shares to New Hires
Reuters  ·  09-10
Mineralys Therapeutics Grants Inducement Equity Awards Covering 52,080 Shares to New Hires
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-10
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat
Reuters  ·  08-26
Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat
Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226
Reuters  ·  08-26
Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226
Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention
Simply Wall St.  ·  08-23
Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention
Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?
Simply Wall St.  ·  08-19
Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?
Mineralys Grants New CMO Inducement Awards for 135,000 Stock Options, 102,400 RSUs
Reuters  ·  08-14
Mineralys Grants New CMO Inducement Awards for 135,000 Stock Options, 102,400 RSUs
Mineralys Therapeutics Reports Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-14
Mineralys Therapeutics Reports Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
TIPRANKS  ·  08-13
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
Mineralys Therapeutics Confronts Heightened Refinancing and Liquidity Risks as 2031 Debt Maturity Looms
TIPRANKS  ·  08-13
Mineralys Therapeutics Confronts Heightened Refinancing and Liquidity Risks as 2031 Debt Maturity Looms
Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares
Reuters  ·  08-13
Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares
Mineralys Therapeutics Names James J. Ferguson III as Chief Medical Officer in Form 3 Beneficial Ownership Filing
Reuters  ·  08-13
Mineralys Therapeutics Names James J. Ferguson III as Chief Medical Officer in Form 3 Beneficial Ownership Filing
Goldman Sachs Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  08-12
Goldman Sachs Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Publishes Corporate Presentation on Lorundrostat for Uncontrolled, Resistant Hypertension and Cardiorenal Diseases
Reuters  ·  08-12
Mineralys Therapeutics Publishes Corporate Presentation on Lorundrostat for Uncontrolled, Resistant Hypertension and Cardiorenal Diseases
Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Mineralys Therapeutics Q2 Loss Widens
MT Newswires Live  ·  08-12
Mineralys Therapeutics Q2 Loss Widens
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss
MT Newswires Live  ·  08-12
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--